BioSig Technologies, Inc. Logo

BioSig Technologies, Inc.

BSGM

(0.0)
Stock Price

0,30 USD

-1048.92% ROA

-6699.94% ROE

-0.78x PER

Market Cap.

27.835.156,00 USD

-50.43% DER

0% Yield

-21275.89% NPM

BioSig Technologies, Inc. Stock Analysis

BioSig Technologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioSig Technologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-2665.07%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-847.8%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

3 PBV

The stock's high Price-to-Book Value (P/BV) ratio (71.9x) suggests it's overvalued, potentially making it an expensive investment.

4 DER

The stock is burdened with a heavy load of debt (176%), making it financially unstable and potentially risky for investors.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

BioSig Technologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioSig Technologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioSig Technologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioSig Technologies, Inc. Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 441.000 100%
2022 286.000 -54.2%
2023 4.000 -7050%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioSig Technologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 992.207
2014 547.996 -81.06%
2015 1.238.548 55.75%
2016 2.654.501 53.34%
2017 4.756.468 44.19%
2018 4.368.784 -8.87%
2019 9.738.819 55.14%
2020 18.136.000 46.3%
2021 5.602.000 -223.74%
2022 5.821.000 3.76%
2023 4.580.000 -27.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioSig Technologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 5.229.252
2014 7.304.440 28.41%
2015 10.795.007 32.34%
2016 8.499.304 -27.01%
2017 8.138.117 -4.44%
2018 12.881.027 36.82%
2019 24.810.712 48.08%
2020 40.954.000 39.42%
2021 27.853.000 -47.04%
2022 21.380.000 -30.28%
2023 11.260.000 -89.88%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioSig Technologies, Inc. EBITDA
Year EBITDA Growth
2013 -6.221.459
2014 -7.852.436 20.77%
2015 -15.147.135 48.16%
2016 -10.730.897 -41.15%
2017 -13.105.050 18.12%
2018 -17.249.811 24.03%
2019 -34.549.983 50.07%
2020 -58.633.000 41.07%
2021 -33.766.000 -73.65%
2022 -26.972.000 -25.19%
2023 -15.832.000 -70.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioSig Technologies, Inc. Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 242.000 100%
2022 229.000 -5.68%
2023 4.000 -5625%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioSig Technologies, Inc. Net Profit
Year Net Profit Growth
2013 -9.804.631
2014 -8.473.040 -15.72%
2015 -9.461.452 10.45%
2016 -11.587.187 18.35%
2017 -12.695.743 8.73%
2018 -17.251.317 26.41%
2019 -33.921.625 49.14%
2020 -52.174.000 34.98%
2021 -31.362.000 -66.36%
2022 -27.271.000 -15%
2023 -18.276.000 -49.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioSig Technologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -1
2014 -2 50%
2015 -2 -100%
2016 -1 0%
2017 -1 0%
2018 -1 0%
2019 -2 0%
2020 -2 0%
2021 -1 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioSig Technologies, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -1.774.175
2014 -2.001.035 11.34%
2015 -4.539.614 55.92%
2016 -5.123.707 11.4%
2017 -7.479.490 31.5%
2018 -10.563.106 29.19%
2019 -15.771.665 33.02%
2020 -26.688.000 40.9%
2021 -26.941.000 0.94%
2022 -21.873.000 -23.17%
2023 -3.888.000 -462.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioSig Technologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -1.762.459
2014 -1.997.072 11.75%
2015 -4.523.751 55.85%
2016 -5.107.452 11.43%
2017 -7.470.054 31.63%
2018 -10.255.427 27.16%
2019 -15.482.982 33.76%
2020 -26.601.000 41.8%
2021 -26.399.000 -0.77%
2022 -21.705.000 -21.63%
2023 -3.828.000 -467.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioSig Technologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 11.716
2014 3.963 -195.63%
2015 15.863 75.02%
2016 16.255 2.41%
2017 9.436 -72.27%
2018 307.679 96.93%
2019 288.683 -6.58%
2020 87.000 -231.82%
2021 542.000 83.95%
2022 168.000 -222.62%
2023 60.000 -180%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioSig Technologies, Inc. Equity
Year Equity Growth
2013 -2.665.448
2014 -872.062 -205.65%
2015 -1.439.631 39.42%
2016 -1.717.204 16.16%
2017 -2.264.844 24.18%
2018 3.799.269 159.61%
2019 11.876.440 68.01%
2020 25.277.000 53.01%
2021 12.565.000 -101.17%
2022 397.000 -3064.99%
2023 -950.000 141.79%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioSig Technologies, Inc. Assets
Year Assets Growth
2013 352.053
2014 353.338 0.36%
2015 1.030.562 65.71%
2016 1.241.958 17.02%
2017 1.700.317 26.96%
2018 4.996.832 65.97%
2019 14.217.113 64.85%
2020 30.386.000 53.21%
2021 15.519.000 -95.8%
2022 4.110.000 -277.59%
2023 3.154.000 -30.31%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioSig Technologies, Inc. Liabilities
Year Liabilities Growth
2013 3.017.501
2014 1.225.400 -146.25%
2015 2.470.193 50.39%
2016 2.959.162 16.52%
2017 3.965.161 25.37%
2018 1.197.563 -231.1%
2019 2.340.673 48.84%
2020 5.109.000 54.19%
2021 2.954.000 -72.95%
2022 3.713.000 20.44%
2023 4.104.000 9.53%

BioSig Technologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.4
Price to Earning Ratio
-0.78x
Price To Sales Ratio
197.41x
POCF Ratio
-1.26
PFCF Ratio
-1.49
Price to Book Ratio
-22.14
EV to Sales
198.43
EV Over EBITDA
-0.97
EV to Operating CashFlow
-1.51
EV to FreeCashFlow
-1.49
Earnings Yield
-1.28
FreeCashFlow Yield
-0.67
Market Cap
0,03 Bil.
Enterprise Value
0,03 Bil.
Graham Number
0.35
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-0.4
Income Quality
0.63
ROE
-67
Return On Assets
-9.51
Return On Capital Employed
38.76
Net Income per EBT
1.01
EBT Per Ebit
1.01
Ebit per Revenue
-208.11
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
170.71
Research & Developement to Revenue
35.72
Stock Based Compensation to Revenue
58.45
Gross Profit Margin
-2.11
Operating Profit Margin
-208.11
Pretax Profit Margin
-209.63
Net Profit Margin
-212.76

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.25
Free CashFlow per Share
-0.25
Capex to Operating CashFlow
0.01
Capex to Revenue
-1.7
Capex to Depreciation
-0.68
Return on Invested Capital
-3309.31
Return on Tangible Assets
-10.49
Days Sales Outstanding
36.24
Days Payables Outstanding
0
Days of Inventory on Hand
2960.56
Receivables Turnover
10.07
Payables Turnover
0
Inventory Turnover
0.12
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,01
Tangible Book Value per Share
-0.02
Shareholders Equity per Share
-0.01
Interest Debt per Share
0.01
Debt to Equity
-0.5
Debt to Assets
0.17
Net Debt to EBITDA
-0
Current Ratio
0.27
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.5
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.09
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
204000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioSig Technologies, Inc. Dividends
Year Dividends Growth

BioSig Technologies, Inc. Profile

About BioSig Technologies, Inc.

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

CEO
Dr. Budimir S. Drakulic Ph.D.
Employee
47
Address
55 Greens Farms Road
Westport, 06880

BioSig Technologies, Inc. Executives & BODs

BioSig Technologies, Inc. Executives & BODs
# Name Age
1 Mr. Andrew Gornell Ballou
Vice President of Investor Relations
70
2 Dr. Budimir S. Drakulic Ph.D.
Chief Scientist
70

BioSig Technologies, Inc. Competitors